Suppliers / Gulbrandsen Technologies

Gulbrandsen Technologies

United States Updated 9 July 2026

Gulbrandsen Technologies is an API manufacturer based in United States. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 16 February 2022 as VAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 February 2022 VAI US FDA
  • 26 August 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Orangeburg, United States 1000111095

What they file, and where

Molecule Regulators Docs
Sucralfate US FDA 1

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. Gulbrandsen Technologies comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 16 February 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability